Kala Pharmaceuticals Stock News

Gainers: Guardforce GFAI +99%.Hycroft Mining Corporation HYMC +59%.Clearside Biomedical CLSD +34%.Kala Pharmaceuticals (KALA) +27%.Lazydays LAZY +24%.4D pharma LBPS +22%.TeraWulf …

Nasdaq Penny Stocks List For March The post 4 Nasdaq Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Buy According To Analysts. The post 4 Penny Stocks With Huge Potential According To Analyst Forecasts appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt

Kala Pharmaceuticals KALA +20%. Natera NTRA +17%. Sunshine Biopharma SBFM -32%. Myomo (MYO) -28%.

NEW YORK , March 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLSA, INDO, USWS, KALA, and NINE. … Full story available on Benzinga.com

4 Hot Penny Stocks To Buy According To Analysts. The post 4 Penny Stocks With Huge Potential According To Analyst Forecasts appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt

Kala Pharmaceuticals (KALA) said that UnitedHealthcare (UNH) added dry eye disease therapy Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its…

-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that UnitedHealthcare, one of the largest commercial health care plans in the United States, covering approximately 13 million lives, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. EYSUVIS now has coverage for approximately 118 million lives, or 70% of all commercial lives.

ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kala Pharmaceuticals Inc (KALA) shares closed today at 1.0% above its 52 week low of $1.01, giving the company a market cap of $68M. The stock is currently down 13.2% year-to-date, down 86.1% over the past 12 months, and down 94.3% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 4.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 326.0% The company's stock price performance over the past 12 months lags the peer average by 378.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kala Pharmaceuticals Inc (KALA) shares closed today at 0.9% above its 52 week low of $1.07, giving the company a market cap of $70M. The stock is currently down 10.7% year-to-date, down 85.8% over the past 12 months, and down 94.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 148.6% The company's stock price performance over the past 12 months lags the peer average by 359.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kala Pharmaceuticals Inc (KALA) shares closed today at 0.9% above its 52 week low of $1.07, giving the company a market cap of $70M. The stock is currently down 10.7% year-to-date, down 84.7% over the past 12 months, and down 94.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 9.2% lower than its 5-day moving average, 17.6% lower than its 20-day moving average, and 48.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 148.6% The company's stock price performance over the past 12 months lags the peer average by 343.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kala Pharmaceuticals Inc (KALA) shares closed 2.5% lower than its previous 52 week low, giving the company a market cap of $78M. The stock is currently down 82.3% year-to-date, down 83.5% over the past 12 months, and down 93.5% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 14.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 702.8% The company's stock price performance over the past 12 months lags the peer average by 763.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.